A Caltech Library Service

Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11

Li, Jing and Zhang, Yaru and Da Silva Sil Dos Santos, Bruno and Wang, Feng and Ma, Yuyong and Perez, Christian and Yang, Yanling and Peng, Junmin and Cohen, Seth M. and Chou, Tsui-Fen and Hilton, Stephen T. and Deshaies, Raymond J. (2018) Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11. Cell Chemical Biology, 25 (11). pp. 1350-1358. ISSN 2451-9456. PMCID PMC6309308. doi:10.1016/j.chembiol.2018.07.012.

[img] PDF - Accepted Version
See Usage Policy.

[img] PDF (Figures S1–S4 and Tables S1 and S2) - Supplemental Material
See Usage Policy.


Use this Persistent URL to link to this item:


The 26S proteasome is the major proteolytic machine for breaking down cytosolic and nuclear proteins in eukaryotes. Due to the lack of a suitable assay, it is difficult to measure routinely and quantitatively the breakdown of proteins by the 26S proteasome in vitro. In the present study, we developed an assay to monitor proteasome-mediated protein degradation. Using this assay, we discovered that epidithiodiketopiperazine (ETPs) blocked the degradation of our model substrate in vitro. Further characterization revealed that ETPs inhibited proteasome function by targeting the essential proteasomal deubiquitinase Rpn11 (POH1/PSMD14). ETPs also inhibited other JAMM (JAB1/MPN/Mov34 metalloenzyme) proteases such as Csn5 and AMSH. An improved ETP with fewer non-specific effects, SOP11, stabilized a subset of proteasome substrates in cells, induced the unfolded protein response, and led to cell death. SOP11 represents a class of Rpn11 inhibitor and provides an alternative route to develop proteasome inhibitors.

Item Type:Article
Related URLs:
URLURL TypeDescription CentralArticle
Cohen, Seth M.0000-0002-5233-2280
Chou, Tsui-Fen0000-0003-2410-2186
Deshaies, Raymond J.0000-0002-3671-9354
Additional Information:© 2018 Elsevier Ltd. Under an Elsevier user license. Received 15 February 2018, Revised 23 May 2018, Accepted 25 July 2018, Available online 23 August 2018. We thank J.M. Huibregtse (The University of Texas at Austin) for the vector expressing GST-Wbp2-C-K222, Rsp5, and Rsp5-E6AP, A. Martin (University of California, Berkeley) for the pETDuet-1 vector expressing the Rpn11-Rpn8 dimer, T.M. Kapoor (The Rockefeller University) for providing the RPE1 WT and BTZ-resistant cell lines, H. Park for testing the cell lines for mycoplasma contamination, A. Bowers (University of North Carolina) for the stimulating discussion on gliotoxin, and D. Sherman (Amgen Inc.) for critical reading of our manuscript. This work was supported by grants from the Caltech Gates Grubstake Fund and Amgen to R.J.D. and from the NIH (CA164803) to R.J.D. and S.M.C. S.T.H. and B.D.S.S.D.S. were supported by the funding from FCT (grant no. SFRH/BD/65630/2009). Author Contributions: J.L. designed, executed, and interpreted the experiments using Wbp2 as proteasome activity substrate, in vitro Rpn11 assay and AMSH assay, and western blot. Y.Z. performed and analyzed the in vitro Csn5 assay, real-time qPCR assay, and western blot. B.D.S.S.D.S. and S.T.H. synthesized ETP compounds SOP1-11. Y.Y. and J.P. quantified the linkage type of ubiquitin chain on Wbp2. F.W. and T.-F.C performed and analyzed the UbG76V-GFP degradation assay. Y.M., C.P. and S.M.C. performed and analyzed the hCAII and MMP-2 assay. R.J.D. designed, interpreted, and oversaw the experiments for the entire study. The manuscript was drafted by J.L. and R.J.D with input from all authors. Declaration of Interests: R.J.D. is a founder, shareholder, and member of the Scientific Advisory Board of Cleave Biosciences, which is engaged in discovery and development of drugs that target enzymes involved in ubiquitin-dependent protein degradation. R.J.D. is currently Senior Vice President of discovery research at Amgen Inc.. S.M.C. is a co-founder and has an equity interest, and receives income as a member of the Scientific Advisory Board for Cleave Biosciences and is a co-founder, has an equity interest, and a member of the Scientific Advisory Board for Forge Therapeutics. Both companies may potentially benefit from the research results of certain projects in the laboratory of S.M.C. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.
Funding AgencyGrant Number
Caltech Gates Grubstake FundUNSPECIFIED
Fundação para a Ciência e a Tecnologia (FCT)SFRH/BD/65630/2009
Subject Keywords:proteasome; Rpn11; POH1; PSMD14; ubiquitin; Capzimin; epidithiodiketopiperazine; gliotoxin; protein degradation; JAMM protease
Issue or Number:11
PubMed Central ID:PMC6309308
Record Number:CaltechAUTHORS:20180823-134532623
Persistent URL:
Official Citation:Jing Li, Yaru Zhang, Bruno Da Silva Sil Dos Santos, Feng Wang, Yuyong Ma, Christian Perez, Yanling Yang, Junmin Peng, Seth M. Cohen, Tsui-Fen Chou, Stephen T. Hilton, Raymond J. Deshaies, Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11, Cell Chemical Biology, Volume 25, Issue 11, 2018, Pages 1350-1358.e9, ISSN 2451-9456,
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:89092
Deposited By: Tony Diaz
Deposited On:23 Aug 2018 21:13
Last Modified:16 Feb 2022 23:48

Repository Staff Only: item control page